Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer

Christos Sotiriou, Trevor J. Powles, Mitch Dowsett, Amir A. Jazaeri, Andrew L. Feldman, Laura Assersohn, Chandramouli Gadisetti, Steven K. Libutti, Edison T. Liu

Research output: Contribution to journalArticle

200 Citations (Scopus)

Abstract

BACKGROUND: Drug resistance in breast cancer is a major obstacle to successful chemotherapy. In this study we used cDNA microarray technology to examine gene expression profiles obtained from fine needle aspiration (FNA) of primary breast tumors before and after systemic chemotherapy. Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and to identify those expression profiles that correlate with treatment response.

METHODS: Repeat presurgical FNA samples were taken from six patients who were to undergo primary surgical treatment. Additionally, a group of 10 patients who were to receive neoadjuvant chemotherapy underwent two FNAs before chemotherapy (adriamycin 60 mg/m2 and cyclophosphamide 600 mg/m2) followed by another FNA on day 21 after the first cycle. Total RNA was amplified with T7 Eberwine's procedure and labeled cDNA was hybridized onto a 7600-feature glass cDNA microarray.

RESULTS: We identified candidate gene expression profiles that might distinguish tumors with complete response to chemotherapy from tumors that do not respond, and found that the number of genes that change after one cycle of chemotherapy was 10 times greater in the responding group than in the non-responding group.

CONCLUSION: This study supports the suitability of FNA-derived cDNA microarray expression profiling of breast cancers as a comprehensive genomic approach for studying the mechanisms of drug resistance. Our findings also demonstrate the potential of monitoring post-chemotherapy changes in expression profiles as a measure of pharmacodynamic effect and suggests that these approaches might yield useful results when validated by larger studies.

Original languageEnglish (US)
Pages (from-to)R3
JournalBreast cancer research : BCR
Volume4
Issue number3
StatePublished - 2002
Externally publishedYes

Fingerprint

Fine Needle Biopsy
Transcriptome
Breast Neoplasms
Drug Therapy
Oligonucleotide Array Sequence Analysis
Drug Resistance
Doxorubicin
Cyclophosphamide
Glass
Neoplasms
Complementary DNA
RNA
Technology
Therapeutics
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sotiriou, C., Powles, T. J., Dowsett, M., Jazaeri, A. A., Feldman, A. L., Assersohn, L., ... Liu, E. T. (2002). Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast cancer research : BCR, 4(3), R3.

Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. / Sotiriou, Christos; Powles, Trevor J.; Dowsett, Mitch; Jazaeri, Amir A.; Feldman, Andrew L.; Assersohn, Laura; Gadisetti, Chandramouli; Libutti, Steven K.; Liu, Edison T.

In: Breast cancer research : BCR, Vol. 4, No. 3, 2002, p. R3.

Research output: Contribution to journalArticle

Sotiriou, C, Powles, TJ, Dowsett, M, Jazaeri, AA, Feldman, AL, Assersohn, L, Gadisetti, C, Libutti, SK & Liu, ET 2002, 'Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer', Breast cancer research : BCR, vol. 4, no. 3, pp. R3.
Sotiriou, Christos ; Powles, Trevor J. ; Dowsett, Mitch ; Jazaeri, Amir A. ; Feldman, Andrew L. ; Assersohn, Laura ; Gadisetti, Chandramouli ; Libutti, Steven K. ; Liu, Edison T. / Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. In: Breast cancer research : BCR. 2002 ; Vol. 4, No. 3. pp. R3.
@article{0e7aefe14dc445fb91bf3098bdc3f012,
title = "Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer",
abstract = "BACKGROUND: Drug resistance in breast cancer is a major obstacle to successful chemotherapy. In this study we used cDNA microarray technology to examine gene expression profiles obtained from fine needle aspiration (FNA) of primary breast tumors before and after systemic chemotherapy. Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and to identify those expression profiles that correlate with treatment response.METHODS: Repeat presurgical FNA samples were taken from six patients who were to undergo primary surgical treatment. Additionally, a group of 10 patients who were to receive neoadjuvant chemotherapy underwent two FNAs before chemotherapy (adriamycin 60 mg/m2 and cyclophosphamide 600 mg/m2) followed by another FNA on day 21 after the first cycle. Total RNA was amplified with T7 Eberwine's procedure and labeled cDNA was hybridized onto a 7600-feature glass cDNA microarray.RESULTS: We identified candidate gene expression profiles that might distinguish tumors with complete response to chemotherapy from tumors that do not respond, and found that the number of genes that change after one cycle of chemotherapy was 10 times greater in the responding group than in the non-responding group.CONCLUSION: This study supports the suitability of FNA-derived cDNA microarray expression profiling of breast cancers as a comprehensive genomic approach for studying the mechanisms of drug resistance. Our findings also demonstrate the potential of monitoring post-chemotherapy changes in expression profiles as a measure of pharmacodynamic effect and suggests that these approaches might yield useful results when validated by larger studies.",
author = "Christos Sotiriou and Powles, {Trevor J.} and Mitch Dowsett and Jazaeri, {Amir A.} and Feldman, {Andrew L.} and Laura Assersohn and Chandramouli Gadisetti and Libutti, {Steven K.} and Liu, {Edison T.}",
year = "2002",
language = "English (US)",
volume = "4",
pages = "R3",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "3",

}

TY - JOUR

T1 - Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer

AU - Sotiriou, Christos

AU - Powles, Trevor J.

AU - Dowsett, Mitch

AU - Jazaeri, Amir A.

AU - Feldman, Andrew L.

AU - Assersohn, Laura

AU - Gadisetti, Chandramouli

AU - Libutti, Steven K.

AU - Liu, Edison T.

PY - 2002

Y1 - 2002

N2 - BACKGROUND: Drug resistance in breast cancer is a major obstacle to successful chemotherapy. In this study we used cDNA microarray technology to examine gene expression profiles obtained from fine needle aspiration (FNA) of primary breast tumors before and after systemic chemotherapy. Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and to identify those expression profiles that correlate with treatment response.METHODS: Repeat presurgical FNA samples were taken from six patients who were to undergo primary surgical treatment. Additionally, a group of 10 patients who were to receive neoadjuvant chemotherapy underwent two FNAs before chemotherapy (adriamycin 60 mg/m2 and cyclophosphamide 600 mg/m2) followed by another FNA on day 21 after the first cycle. Total RNA was amplified with T7 Eberwine's procedure and labeled cDNA was hybridized onto a 7600-feature glass cDNA microarray.RESULTS: We identified candidate gene expression profiles that might distinguish tumors with complete response to chemotherapy from tumors that do not respond, and found that the number of genes that change after one cycle of chemotherapy was 10 times greater in the responding group than in the non-responding group.CONCLUSION: This study supports the suitability of FNA-derived cDNA microarray expression profiling of breast cancers as a comprehensive genomic approach for studying the mechanisms of drug resistance. Our findings also demonstrate the potential of monitoring post-chemotherapy changes in expression profiles as a measure of pharmacodynamic effect and suggests that these approaches might yield useful results when validated by larger studies.

AB - BACKGROUND: Drug resistance in breast cancer is a major obstacle to successful chemotherapy. In this study we used cDNA microarray technology to examine gene expression profiles obtained from fine needle aspiration (FNA) of primary breast tumors before and after systemic chemotherapy. Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and to identify those expression profiles that correlate with treatment response.METHODS: Repeat presurgical FNA samples were taken from six patients who were to undergo primary surgical treatment. Additionally, a group of 10 patients who were to receive neoadjuvant chemotherapy underwent two FNAs before chemotherapy (adriamycin 60 mg/m2 and cyclophosphamide 600 mg/m2) followed by another FNA on day 21 after the first cycle. Total RNA was amplified with T7 Eberwine's procedure and labeled cDNA was hybridized onto a 7600-feature glass cDNA microarray.RESULTS: We identified candidate gene expression profiles that might distinguish tumors with complete response to chemotherapy from tumors that do not respond, and found that the number of genes that change after one cycle of chemotherapy was 10 times greater in the responding group than in the non-responding group.CONCLUSION: This study supports the suitability of FNA-derived cDNA microarray expression profiling of breast cancers as a comprehensive genomic approach for studying the mechanisms of drug resistance. Our findings also demonstrate the potential of monitoring post-chemotherapy changes in expression profiles as a measure of pharmacodynamic effect and suggests that these approaches might yield useful results when validated by larger studies.

UR - http://www.scopus.com/inward/record.url?scp=13844311931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844311931&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - R3

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 3

ER -